|
EP2630952A1
|
|
Self-preserved oil dispersions comprising boric acid
|
|
AU2012200251A1
|
|
Ophthalmic emulsions containing an immunosuppressive agent
|
|
WO2012028733A1
|
|
A water-in-oil type emulsion for treating a disease of the eye
|
|
WO2011067384A1
|
|
In vitro method for testing toxicity and efficacy of a test material to an ocular surface
|
|
EP2425814A1
|
|
A water-in-oil type emulsion for treating a disease of the eye
|
|
EP2389939A1
|
|
Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
|
|
EP2394636A1
|
|
Method for treating retinal conditions using an intraocular tamponade
|
|
EP2228058A1
|
|
Anionic oil-in-water emulsion containing prostaglandins and uses thereof
|
|
EP2228057A1
|
|
Cationic oil-in-water emulsions containing prostaglandins and uses thereof
|
|
KR20100093585A
|
|
Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
|
|
WO2009007409A2
|
|
Oil in water emulsion comprising nsaids and quaternary ammonium halides
|
|
EP2077104A1
|
|
Micellar compositions with ophtalmic applications
|
|
US2009170944A1
|
|
Ophthalmic micellar compositions with enhanced stability
|
|
US2009169629A1
|
|
Micellar compositions with ophthalmic applications
|
|
EP2077105A1
|
|
Ophthalmic Micellar Compositions with Enhanced Stability
|
|
US2009124565A1
|
|
Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
|
|
EP2060262A1
|
|
Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc
|
|
WO2008035246A2
|
|
Compositions containing quaternary ammonium compounds
|
|
EP2016936A1
|
|
Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
|
|
KR20140027520A
|
|
Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
|
